Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Consolidated Net Income: 2021-2025

Historic Consolidated Net Income for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $7.4 million.

  • Arcutis Biotherapeutics' Consolidated Net Income rose 117.84% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 77.33%. This contributed to the annual value of -$140.0 million for FY2024, which is 46.58% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Consolidated Net Income stood at $7.4 million for Q3 2025, which was up 146.64% from -$15.9 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Consolidated Net Income high stood at $7.4 million for Q3 2025, and its period low was -$107.7 million during Q3 2022.
  • In the last 3 years, Arcutis Biotherapeutics' Consolidated Net Income had a median value of -$41.5 million in 2024 and averaged -$39.6 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Consolidated Net Income tumbled by 88.70% in 2022, and later spiked by 117.84% in 2025.
  • Arcutis Biotherapeutics' Consolidated Net Income (Quarterly) stood at -$71.3 million in 2021, then declined by 1.03% to -$72.0 million in 2022, then rose by 7.96% to -$66.3 million in 2023, then spiked by 83.72% to -$10.8 million in 2024, then spiked by 117.84% to $7.4 million in 2025.
  • Its Consolidated Net Income stands at $7.4 million for Q3 2025, versus -$15.9 million for Q2 2025 and -$25.1 million for Q1 2025.